| Study marks the emergence of disease-modifying treatments for autism spectrum disorders |
 |
| December 16, 2010 |
|
| Boston, Mass. -- Researchers at Children's Hospital Boston have begun a randomized, placebo-controlled trial to test a potential drug treatment for Rett syndrome, the leading known genetic cause of autism in girls. The drug, mecasermin, a synthetic form of insulin-like growth factor-1 (IGF-1), is already FDA-approved for children with short stature due to IGF-1 deficiency. Read more |
5 hours ago
